Cost of clinical negligence claims is rising at a faster rate year-on-year than NHS funding
News
3 UK wins in Practice to Policy Health Awards
Wins for Cambridge University Hospitals, The PBC Foundation and Nottingham University Hospitals
FDA puts Bristol-Myers Squibb Opdivo trials on hold
Decision follows halting of Keytruda trials in July due to potential risks to patients
Bioverativ and Bicycle Therapeutics team up in haemophilia
Deal could be worth over $420 million
Novo Nordisk resolves US federal investigation into marketing practices
Company will pay out over $58 million to settle accusations of misleading doctors, among other claims
EC approves for Merck’s Keytruda for bladder cancer indication
New approval targets locally advanced or metastatic urothelial carcinoma
Method Medical Media launches
London-based agency begins trading today
Destiny Pharma listed on London Stock Exchange
Brighton, UK-based Destiny Pharma has been successfully listed shares on London Stock Exchange with a market capitalisation of £65.4 million, marking the second biotech company to float this year in the UK.
Novartis’ Gilenya hits targets in paediatric MS trial
Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.
Merck considers future of consumer health unit
Germany’s Merck is considering the future of its consumer health segment, including a potential full or partial sale of the business as well as new strategic partnerships.
Mundipharma bags rights to sell Janssen’s Invokana, Vokanamet
Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland.
FDA holds trials of Cellectis’ cell therapy after patient death
US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
More entrants, more companies, more competition!
Rewarding the best marketing talent in pharma, the PharmaTimes Marketer of the Year gala awards and dinner will take place at in London on Thursday 9 November, alongside Communications Team of the Year. Entry to both competitions is now closed. If you are still keen to enter or you’ve just missed the deadline, please email samuel.mcintyre@pharmatimes.com and we will contact you should any places become available at a later date.
Roche’s Alecensa gets green light for early access scheme
UK patients with a rare form of lung cancer will be able to access Roche’s Alecensa without the need for prior chemotherapy before official approval is obtained, following its inclusion in the country’s Early Access to Medicines Scheme.
Pfizer’s Mylotarg returns to market after seven-year hiatus
US regulators have issued a green light for Pfizer’s Mylotarg as a treatment for acute myeloid leukaemia (AML), seven years after the drug was with voluntarily withdrawn from the market.
